2022 Partners

Crown Bioscience

Crown Bioscience
Lead Partner

Crown Bioscience is a cutting-edge translational technology company providing drug discovery and preclinical development services in the areas of oncology, immunology,
inflammation, cardiovascular, and metabolic disease. We bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates. Our premier
translational platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs.




Screen Group
Expertise Partner

SCREEN is a leader in the areas of imaging and electronics technology. Scientists at SCREEN have implemented their technology in the Life Sciences by developing robust,
versatile imaging platforms with a broad spectrum of applications for 2D and 3D in vitro and ex vivo assays to perform high-speed imaging and analysis of the phenotypic and morphological changes in complex 3D cellular/tissue structures. Additionally, SCREEN’s MED64 electrophysiology platforms provide the most-sensitive microelectrode arrays for
label-free functional assays with stem cell-derived cardiomyocytes or/and neurons. SCREEN technology is accelerating research in the field of regenerative medicine, multiple disease areas including oncology/immune-oncology and neurodegenerative diseases.


Newcells Biotech Logo

Newcells Biotech 
Expertise Partner

Newcells Biotech is a fast-growing team of global scientific and industry experts based in state-of-the-art facilities in the Helix Science Campus of Newcastle-upon-Tyne in the UK.
Our purpose is to bridge the gap between scientific discovery and patients and we make a difference by providing better predictions of clinical outcomes. Using our expertise in
induced pluripotent stem cells (iPSCs), cellular physiology, and organoid technology, we build functional preclinical in vitro models of retina, kidney, liver, and lung.




Spotlight Partner

Curi Bio provides a seamless, bioengineered integration of human stem cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues—with a focus on cardiac, skeletal muscle, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new therapeutics. Curi seeks to de-risk and expedite the development of new drugs by decreasing the industry’s dependence on animal models, which often fail to translate to humans. By providing researchers human-relevant preclinical data at the earliest stages of the development pipeline, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.



Spotlight Partner

CELLINK is the leading bio-convergence company and a global provider of technologies, products and services to create, understand and master biology. With a focus on the areas of bioprinting, biosciences and industrial solutions, the company develops and markets innovative technologies that enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical and cosmetic industries. CELLINK’s products are trusted by more than 1,800 laboratories, including ones at all the top 20 pharmaceutical companies, are being used in more than 60 countries, and have been cited in more than 700 publications.
CELLINK is creating the future of medicine.
CELLINK is listed on the Nasdaq Stockholm Main Market under CLNK B.